Oxidative stress-related genetic variants, pro-and antioxidant intake and status, and advanced prostate cancer risk

Cancer Epidemiology Biomarkers and Prevention

Volumn 24, Issue 1, 2015, Pages 178-186

  Geybels, Milan S ^a   Van Den Brandt, Piet A ^a   Van Schooten, Frederik J ^a   Verhage, Bas A J ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ASCORBIC ACID; BETA CAROTENE; CATALASE; CATECHIN; COPPER ZINC SUPEROXIDE DISMUTASE; GLUTATHIONE PEROXIDASE 1; HEME; MANGANESE SUPEROXIDE DISMUTASE; ANTIOXIDANT;

ADULT; ADVANCED CANCER; AGED; ALLELE; ARTICLE; CANCER RISK; CANCER STAGING; CONTROLLED STUDY; DIETARY INTAKE; FOLLOW UP; GENETIC VARIABILITY; GENOTYPE; GENOTYPE ENVIRONMENT INTERACTION; HUMAN; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL; PROSTATE CANCER; SINGLE NUCLEOTIDE POLYMORPHISM; COHORT ANALYSIS; GENETICS; MIDDLE AGED; PROSPECTIVE STUDY; PROSTATE TUMOR; RISK FACTOR;

AGED; ANTIOXIDANTS; COHORT STUDIES; GENETIC VARIATION; HUMANS; MALE; MIDDLE AGED; OXIDATIVE STRESS; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 84921047433     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-14-0968     Document Type: Article

References (52)

1. Droge W. Free radicals in the physiological control of cell function. Physiol Rev 2002;82:47-95.
2. Valko M, Rhodes CJ, Moncol J, Izakovic M, Mazur M. Free radicals, metals and antioxidants in oxidative stress-induced cancer. Chem Biol Interact 2006;160:1-40.
3. Fang YZ, Yang S, Wu G. Free radicals, antioxidants, and nutrition. Nutrition 2002;18:872-9.
4. Mates JM. Effects of antioxidant enzymes in the molecular control of reactive oxygen species toxicology. Toxicology 2000;153:83-104.
5. Finkel T, HolbrookNJ.Oxidants, oxidative stress and the biology of ageing. Nature 2000;408:239-47.
6. Khandrika L, Kumar B, Koul S, Maroni P, Koul HK. Oxidative stress in prostate cancer. Cancer Lett 2009;282:125-36.
7. Minelli A, Bellezza I, ConteC, Culig Z. Oxidative stress-related aging: a role for prostate cancer? Biochim Biophys Acta 2009;1795:83-91.
8. Vance TM, Su J, Fontham ET, Koo SI, Chun OK. Dietary antioxidants and prostate cancer: a review. Nutr Cancer 2013;65:793-801.
9. Wei MY, Giovannucci EL. Lycopene, tomato products, and prostate cancer incidence: a review and reassessment in the PSA screening era. J Oncol 2012;2012:271063.
10. Hurst R, Hooper L, Norat T, Lau R, Aune D, Greenwood DC, et al. Selenium and prostate cancer: systematic review and meta-analysis. Am J Clin Nutr 2012;96:111-22.
11. Geybels MS, Verhage BA, van Schooten FJ, Goldbohm RA, van den Brandt PA. Advanced prostate cancer risk in relation to toenail selenium levels. J Natl Cancer Inst 2013;105:1394-401.
12. van den Brandt PA, Zeegers MP, Bode P, Goldbohm RA. Toenail selenium levels and the subsequent risk of prostate cancer: a prospective cohort study. Cancer Epidemiol Biomarkers Prev 2003;12:866-71.
13. Heinonen OP, Albanes D, Virtamo J, Taylor PR, Huttunen JK, Hartman AM, et al. Prostate cancer and supplementation with alpha-tocopherol and beta-carotene: incidence and mortality in a controlled trial. J Natl Cancer Inst 1998;90:440-6.
14. Duffield-Lillico AJ, Dalkin BL, Reid ME, Turnbull BW, Slate EH, Jacobs ET, et al. Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial. BJU Int 2003;91:608-12.
15. Klein EA, Thompson IM Jr, Tangen CM, Crowley JJ, Lucia MS, Goodman PJ, et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2011;306:1549-56.
16. Choi JY, Neuhouser ML, Barnett MJ, Hong CC, Kristal AR, Thornquist MD, et al. Iron intake, oxidative stress-related genes (MnSOD and MPO) and prostate cancer risk in CARET cohort. Carcinogenesis 2008;29:964-70.
17. Geybels MS, Verhage BA, van Schooten FJ, van den Brandt PA. Measures of combined antioxidant and pro-oxidant exposures and risk of overall and advanced stage prostate cancer. Ann Epidemiol 2012;22:814-20.
18. Jakszyn PG, Allen NE, Lujan-Barroso L, Gonzalez CA, Key TJ, Fonseca-Nunes A, et al. Nitrosamines and heme iron and risk of prostate cancer in the European prospective investigation into cancer and nutrition. Cancer Epidemiol Biomarkers Prev 2012;21:547-51.
19. Rota M, Scotti L, Turati F, Tramacere I, Islami F, Bellocco R, et al. Alcohol consumption and prostate cancer risk: a meta-analysis of the dose-risk relation. Eur J Cancer Prev 2012;21:350-9.
20. Zu K, Giovannucci E. Smoking and aggressive prostate cancer: a review of the epidemiologic evidence. Cancer Causes Control 2009;20: 1799-810.
21. Kang D, Lee KM, Park SK, Berndt SI, Peters U, Reding D, et al. Functional variant of manganese superoxide dismutase (SOD2 V16A) polymorphism is associated with prostate cancer risk in the prostate, lung, colorectal, and ovarian cancer study. Cancer Epidemiol Biomarkers Prev 2007;16:1581-6.
22. Stevens VL, Rodriguez C, Talbot JT, Pavluck AL, Thun MJ, Calle EE. Paraoxonase 1 (PON1) polymorphisms and prostate cancer in the CPSII Nutrition Cohort. Prostate 2008;68:1336-40.
23. Geybels MS, van den Brandt PA, Schouten LJ, van Schooten FJ, van Breda SG, Rayman MP, et al. Selenoprotein gene variants, toenail selenium levels, and risk for advanced prostate cancer. J Natl Cancer Inst 2014;106:dju003.
24. Lee KM, Kang D, Park SK, Berndt SI, Reding D, Chatterjee N, et al. Nitric oxide synthase gene polymorphisms and prostate cancer risk. Carcinogenesis 2009;30:621-5.
25. Zhang J, Dhakal IB, Greene G, Lang NP, Kadlubar FF. Polymorphisms in hOGG1 and XRCC1 and risk of prostate cancer: effects modified by plasma antioxidants. Urology 2010;75:779-85.
26. Crawford A, Fassett RG, Geraghty DP, Kunde DA, Ball MJ, Robertson IK, et al. Relationships between single nucleotide polymorphisms of antioxidant enzymes and disease. Gene 2012;501:89-103.
27. Eeles RA, Olama AA, Benlloch S, Saunders EJ, Leongamornlert DA, Tymrakiewicz M, et al. Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. Nat Genet 2013;45:385-91, 91e1-2.
28. Li H, Kantoff PW, Giovannucci E, Leitzmann MF, Gaziano JM, Stampfer MJ, et al. Manganese superoxide dismutase polymorphism, prediagnostic antioxidant status, and risk of clinical significant prostate cancer. Cancer Res 2005;65:2498-504.
29. Bostwick DG, Grignon DJ, Hammond ME, Amin MB, Cohen M, Crawford D, et al. Prognostic factors in prostate cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 2000;124: 995-1000.
30. van den Brandt PA, Goldbohm RA, van 't Veer P, Volovics A, Hermus RJ, Sturmans F. A large-scale prospective cohort study on diet and cancer in The Netherlands. J Clin Epidemiol 1990;43:285-95.
31. van den Brandt PA, Schouten LJ, Goldbohm RA, Dorant E, Hunen PM. Development of a record linkage protocol for use in the Dutch Cancer Registry for epidemiological research. Int J Epidemiol 1990;19:553-8.
32. Goldbohm RA, van den Brandt PA, Dorant E. Estimation of the coverage of Dutch municipalities by cancer registries and PALGA based on hospital discharge data. Tijdschr Soc Gezondheidsz 1994;19:80-4.
33. Barlow WE, Ichikawa L, RosnerD, Izumi S. Analysis of case-cohort designs. J Clin Epidemiol 1999;52:1165-72.
34. Sobin L, Gospodarowicz M, Wittekind C. TNM Classification of Malignant Tumors. 7th ed. Oxford, UK: Wiley-Blackwell; 2009.
35. van Breda SG, Hogervorst JG, Schouten LJ, Knaapen AM, van Delft JH, Goldbohm RA, et al. Toenails: an easily accessible and long-term stable source of DNA for genetic analyses in large-scale epidemiological studies. Clin Chem 2007;53:1168-70.
36. Choi JY, Neuhouser ML, Barnett M, Hudson M, Kristal AR, Thornquist M, et al. Polymorphisms in oxidative stress-related genes are not associated with prostate cancer risk in heavy smokers. Cancer Epidemiol Biomarkers Prev 2007;16:1115-20.
37. Geybels MS, Hutter CM, Kwon EM, Ostrander EA, Fu R, Feng Z, et al. Variation in selenoenzyme genes and prostate cancer risk and survival. Prostate 2013;73:734-42.
38. Steinbrecher A, Rohrmann S, Timofeeva M, Risch A, Jansen E, Linseisen J. Dietary glucosinolate intake, polymorphisms in selected biotransformation enzymes, and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2010;19:135-43.
39. Abe M, Xie W, Regan MM, King IB, Stampfer MJ, Kantoff PW, et al. Singlenucleotide polymorphisms within the antioxidant defence system and associations with aggressive prostate cancer. BJU Int 2011;107:126-34.
40. Goldbohm RA, van den Brandt PA, Brants HA, van't Veer P, Al M, Sturmans F, et al. Validation of a dietary questionnaire used in a largescale prospective cohort study on diet and cancer. Eur J Clin Nutr 1994; 48:253-65.
41. Goldbohm RA, van't Veer P, van den Brandt PA, van't Hof MA, Brants HA, Sturmans F, et al. Reproducibility of a food frequency questionnaire and stability of dietary habits determined from five annually repeated measurements. Eur J Clin Nutr 1995;49:420-9.
42. Geybels MS, Verhage BA, Arts IC, van Schooten FJ, Goldbohm RA, van den Brandt PA. Dietary flavonoid intake, black tea consumption, and risk of overall and advanced stage prostate cancer. Am J Epidemiol 2013;177: 1388-98.
43. Lin DY, Wei LY. The robust inference for the Cox proportional hazards model. J Am Stat Assoc 1989;84:1074-8.
44. Grambsch PM, Therneau TM. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 1994;81:515-26.
45. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Statist Soc 1995;57: 289-300.
46. Smith NL, Hindorff LA, Heckbert SR, Lemaitre RN, Marciante KD, Rice K, et al. Association of genetic variations with nonfatal venous thrombosis in postmenopausal women. JAMA 2007;297:489-98.
47. Storey JD, Tibshirani R. Statistical significance for genome-wide studies. Proc Natl Acad Sci U S A 2003;100:9440-5.
48. Benjamini Y, Yekutieli D. Quantitative trait Loci analysis using the false discovery rate. Genetics 2005;171:783-90.
49. Forsberg L, Lyrenas L, de Faire U, Morgenstern R. A common functional C-T substitution polymorphismin the promoter region of the human catalase gene influences transcription factor binding, reporter gene transcription and is correlated to blood catalase levels. Free Radic Biol Med 2001;30: 500-5.
50. Tefik T, Kucukgergin C, Sanli O, Oktar T, Seckin S, Ozsoy C. Manganese superoxide dismutase Ile58Thr, catalase C-262T and myeloperoxidase G-463A gene polymorphisms in patients with prostate cancer: relation to advanced and metastatic disease. BJU Int 2013; 112:E406-14.
51. Ahn J, Nowell S, McCann SE, Yu J, Carter L, Lang NP, et al. Associations between catalase phenotype and genotype: modification by epidemiologic factors. Cancer Epidemiol Biomarkers Prev 2006;15:1217-22.
52. Cornelis MC, Tchetgen EJ, Liang L, Qi L, Chatterjee N, Hu FB, et al. Geneenvironment interactions in genome-wide association studies: a comparative study of tests applied to empirical studies of type 2 diabetes. Am J Epidemiol 2012;175:191-202.